FDA Approves Bravnetsa, an Equivalent to Lutathera, for GEP-NETs

The FDA has granted final approval to BRAVNETSA (lutetium Lu 177 dotatate) for the treatment of adults with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The approval includes GEP-NETs originating in the foregut, midgut and hindgut. BRAVNETSA is a radiopharmaceutical that is bioequivalent and therapeutically equivalent to LUTATHERA (lutetium Lu 177 dotatate).

The treatment was approved through the FDA's Abbreviated New Drug Application (ANDA) pathway. According to Lantheus, the manufacturer of BRAVNETSA, it is the first radioligand therapy approved through this pathway and the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA.

What This Means for Patients

GEP-NETs are rare cancers that can develop in the digestive system and pancreas. They can be either functional or nonfunctional depending on whether they produce hormones.

The company estimates that approximately 200,000 people in the United States are living with GEP-NETs. Because these tumors can grow slowly and may cause nonspecific symptoms, diagnosis can sometimes be challenging.

The approval of BRAVNETSA provides another FDA-approved radiopharmaceutical option for adults whose tumors are SSTR-positive.

BRAVNETSA Safety Information

Because BRAVNETSA is a radiopharmaceutical, treatment carries risks associated with radiation exposure. Radioactivity may be detected in urine for up to 30 days following treatment, and patients are given instructions to reduce radiation exposure to themselves and others following administration.

Other warnings and precautions include myelosuppression, secondary myelodysplastic syndrome and leukemia, kidney toxicity, liver toxicity, hypersensitivity reactions and neuroendocrine hormonal crises. BRAVNETSA may also cause fetal harm and infertility.

The most common severe adverse reactions reported with lutetium Lu 177 dotatate include lymphopenia, increased GGT, vomiting, nausea, increased AST and ALT, hyperglycemia and hypokalemia.

Patients receiving BRAVNETSA will also need to follow specific instructions involving somatostatin analogs before and during treatment.

What Comes Next

According to Lantheus, the company is preparing for the launch of BRAVNETSA and working to establish the commercial and operational capabilities needed to support its availability.

For adults living with SSTR-positive GEP-NETs, the approval adds another FDA-approved radiopharmaceutical to the treatment landscape.

Patients should talk with their oncology team about whether BRAVNETSA is appropriate for their specific type of neuroendocrine tumor and individual treatment history.

References

1. Lantheus Holdings, Inc. “Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs.” Sept. 22, 2026.